Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease.

ABSTRACT:

Importance

Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology.

Objective

To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]).

Design, setting, and participants

This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohor

SUBMITTER: Salvado G 

PROVIDER: S-EPMC12558403 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature